Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)

Study Overview
=================
Brief Summary
-----------------
Describe the application status of different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), observe the therapeutic efficacy and safety of the treatment modalities.

Detailed Description
-----------------
Evaluated the efficacy and safety of different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL)

Official Title
-----------------
A Single-center, Non-interventionary Clinical Study Evaluating the Efficacy and Safety of Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)

Conditions
-----------------
Lymphoma, Non-Hodgkin

Intervention / Treatment
-----------------
* Drug: immunochemotherapies


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years old Initial or first recurrent iNHL confirmed by histopathology, including FL (1-3a), MZL, MCL; Sign an informed consent form; Researchers evaluate patients who can benefit from receiving immunochemotherapy. Exclusion Criteria: There are contraindications to any medication in the treatment plan; Pregnant or lactating women or male and female participants of childbearing age did not take contraceptive measures during the trial period and within 30 days after the last medication; Researchers believe that patients who are not suitable for enrollment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| iNHL<br>Different immunochemotherapies in small B-cell non-Hodgkin lymphoma | Drug: immunochemotherapies<br>* Observing different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), which are chosen by investigators, such as RCHOP, BR, RCVP, etc.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ORR | the ratio of numbers of patients with complete response and partial response to all the participants receiving treatment | up to 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 2-year progression-free survival (PFS) | the period from the date of patients sign informed consent to the observed progression of the disease or the occurrence of death for any reason | From date of patients sign informed consent until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years | 
| 2-year event-free survival (EFS) | the period from the date of patients sign informed consent to the observed event for any reason | From date of patients sign informed consent until the date of first documented event, progression or date of death from any cause, whichever came first, assessed up to 2 years | 
| overall survival | time between the date of patients sign informed consent and the date of death or the date of last follow-up time | From date of patients sign informed consent until the date of death or the date of last follow-up time, whichever came first, assessed up to 2 years | 
| Hematology and non hematology toxicity | number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | Throughout the treatment period，up to 6 months |